WO2021031997A1 - Dérivé de dihydropyrimidine et son utilisation - Google Patents

Dérivé de dihydropyrimidine et son utilisation Download PDF

Info

Publication number
WO2021031997A1
WO2021031997A1 PCT/CN2020/109140 CN2020109140W WO2021031997A1 WO 2021031997 A1 WO2021031997 A1 WO 2021031997A1 CN 2020109140 W CN2020109140 W CN 2020109140W WO 2021031997 A1 WO2021031997 A1 WO 2021031997A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
alkyl
haloalkyl
halogen
cycloalkyl
Prior art date
Application number
PCT/CN2020/109140
Other languages
English (en)
Chinese (zh)
Inventor
沙薇
刘洋
孔晓博
李建永
Original Assignee
西藏天晟泰丰药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西藏天晟泰丰药业有限公司 filed Critical 西藏天晟泰丰药业有限公司
Priority to CN202080057115.8A priority Critical patent/CN114341137A/zh
Publication of WO2021031997A1 publication Critical patent/WO2021031997A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un dérivé de dihydropyrimidine de formule générale (I), qui peut être utilisé pour le traitement et la prévention d'une infection par le virus de l'hépatite B. L'invention concerne en outre une composition pharmaceutique contenant le composé de formule générale (I), et son utilisation pour le traitement et la prévention d'une infection par le virus de l'hépatite B.
PCT/CN2020/109140 2019-08-16 2020-08-14 Dérivé de dihydropyrimidine et son utilisation WO2021031997A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080057115.8A CN114341137A (zh) 2019-08-16 2020-08-14 二氢嘧啶衍生物及其用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910758274 2019-08-16
CN201910758274.X 2019-08-16
CN202010807791.4 2020-08-12
CN202010807791 2020-08-12

Publications (1)

Publication Number Publication Date
WO2021031997A1 true WO2021031997A1 (fr) 2021-02-25

Family

ID=74659909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/109140 WO2021031997A1 (fr) 2019-08-16 2020-08-14 Dérivé de dihydropyrimidine et son utilisation

Country Status (3)

Country Link
CN (1) CN114341137A (fr)
TW (1) TW202115079A (fr)
WO (1) WO2021031997A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015180631A1 (fr) * 2014-05-30 2015-12-03 南京明德新药研发股份有限公司 Dérivé de boucle dihydropyrimido à titre d'inhibiteur du vhb
WO2017011552A1 (fr) * 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
WO2017076286A1 (fr) * 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 Forme cristalline, procédé de préparation et intermédiaire d'un composé à cycle dihydropyridine
WO2017214395A1 (fr) * 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hépatite b
WO2019113175A1 (fr) * 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
WO2019113173A1 (fr) * 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hépatite b
WO2020001592A1 (fr) * 2018-06-28 2020-01-02 河南天晟泰丰医药科技有限公司 Dérivés de dihydropyrimidine et leur utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015180631A1 (fr) * 2014-05-30 2015-12-03 南京明德新药研发股份有限公司 Dérivé de boucle dihydropyrimido à titre d'inhibiteur du vhb
WO2017011552A1 (fr) * 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
WO2017076286A1 (fr) * 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 Forme cristalline, procédé de préparation et intermédiaire d'un composé à cycle dihydropyridine
WO2017214395A1 (fr) * 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hépatite b
WO2019113175A1 (fr) * 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
WO2019113173A1 (fr) * 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Agents antiviraux contre l'hépatite b
WO2020001592A1 (fr) * 2018-06-28 2020-01-02 河南天晟泰丰医药科技有限公司 Dérivés de dihydropyrimidine et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SONG LI TING, LIU RUI RUI, ZHAI HONG LIN, MENG YA JIE, ZHU MIN: "Molecular mechanisms of tetrahydropyrrolo[1, 2-c]pyrimidines as HBV capsid assembly inhibitors", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 663, 15 March 2019 (2019-03-15), pages 1 - 10, XP055782355, ISSN: 0003-9861, DOI: 10.1016/j.abb.2018.12.029 *

Also Published As

Publication number Publication date
CN114341137A (zh) 2022-04-12
TW202115079A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
CN109803972B (zh) 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
RU2745431C1 (ru) Гетероарильное производное пиперазина, способ его получения и применение в медицине
CN110437205B (zh) 吡啶烯基哌啶衍生物及其用途
JP2017128605A (ja) 抗ウイルス化合物の固体形態
PT2595980E (pt) Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
CN106883279B (zh) 一种前药、其制备方法、药物组合物及其用途
TW201605885A (zh) 尿嘧啶核苷酸類似物及其製備方法和應用
BR112020018094A2 (pt) Compostos de aminopirazina diol como inibidores de pi3k-¿
WO2020001592A1 (fr) Dérivés de dihydropyrimidine et leur utilisation
CA3190495A1 (fr) Composes, compositions et methodes
WO2020057546A1 (fr) Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation
WO2021129841A1 (fr) Composé utilisé comme inhibiteur de kinase ret et son application
JP2023145644A (ja) ジヒドロイソキノリン系化合物
WO2020259703A1 (fr) Composé de pyrazolopyrimidine, son procédé de préparation et ses applications
WO2023056936A1 (fr) Dérivé nucléotidique, composition pharmaceutique associée et son utilisation
WO2022194252A1 (fr) Formes polymorphes de composé, leur procédé de préparation et leur utilisation
WO2019219070A1 (fr) Oligonucléotide deutéré et promédicament
WO2021031997A1 (fr) Dérivé de dihydropyrimidine et son utilisation
CN107089955B (zh) 磺酰胺类衍生物及其制备方法和用途
EP4174068A1 (fr) Nouveau composé et composition pharmaceutique le comprenant pour prévenir ou traiter un cancer résistant
CN114057823B (zh) 白桦脂酸衍生物，其制备方法、药物组合物和应用
WO2021233133A1 (fr) Composé utilisé comme inhibiteur de kinase ret et son application
CN111484541B (zh) 双核苷酸前体药物及其制备方法
WO2020140894A1 (fr) Composé de benzothiophène substitué contenant du fluor, composition pharmaceutique et application de celui-ci
CN112218878A (zh) Ntcp抑制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20854424

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20854424

Country of ref document: EP

Kind code of ref document: A1